600 patients66,869 observations120 daysLIVE

Patient P-01732

Synthetic patientNBL-101 · Day 104 · 65–74 · M · baseline S14Open companion preview
Therapy response
Stable
Tolerance
Deteriorating
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
94%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S14
  2. Day 45 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 57 ME-01 recommendedMonitoring Escalation ME-01
  4. Day 58 Patient acceptedStarted ME-01 in the companion
  5. Day 61 Deterioration detected before clinical escalationMonitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 45.

Primary contributors, last 14 days
  • Toxicity+11
  • GI instability-5
  • Inflammatory activity+4

What helped?

  • Monitoring Escalation ME-01Day 57
    Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
90%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 83% showed improvement
  • median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 39/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Mucosal barrier integrity 60
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 59 and rising
    • WearableSleep 6.1 h, below personal baseline
  • Inflammatory signalling 45
    • MicrobiomeBacteroides fragilis expansion
    • BloodInflammatory load index 63
  • Autonomic recovery 45
    • WearableResting HR 81 bpm
    • WearableShort sleep window
  • Drug metabolism and exposure 20
    • BloodToxicity index 56
DNA
Fictional pharmacogenomic panel
  • CYP2D6 Rapid metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 39/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisHigh
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
38 ms
Sleep
5.8 h
Steps
6,672
Resting HR
80 bpm
Daily log: GI score 59, nutritional resilience 40, adherence 45.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • Keep the current walking rhythm
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0175160%S14ME-01improved48
P-0164659%S14GI-04no change42
P-0131158%S14ME-01improved49
P-0160556%S14ME-01improved41
P-0183455%S14NP-02improved44
P-0159554%S14GI-04no change51
P-0165654%S14ME-01improved41
P-0173554%S1440
P-0146553%S14NP-02improved56
P-0156452%S14ME-01improved39
P-0184352%S14SC-12no change45
P-0176051%S1442